Extended-release naltrexone for treatment of alcohol dependence in primary care

Joshua D. Lee, Ellie Grossman, Danae DiRocco, Andrea Truncali, Kathleen Hanley, David Stevens, John Rotrosen, Marc N. Gourevitch

Research output: Contribution to journalArticlepeer-review


The feasibility of using extended-release injectable naltrexone (XR-NTX) to treat alcohol dependence in routine primary care settings is unknown. An open-label, observational cohort study evaluated 3-month treatment retention, patient satisfaction, and alcohol use among alcohol-dependent patients in two urban public hospital medical clinics. Adults seeking treatment were offered monthly medical management (MM) and three XR-NTX injections (380 mg, intramuscular). Physician-delivered MM emphasized alcohol abstinence, medication effects, and accessing mutual help and counseling resources. Seventy-two alcohol-dependent patients were enrolled; 90% (65 of 72) of eligible subjects received the first XR-NTX injection; 75% (49 of 65) initiating treatment received the second XR-NTX injection; 62% (40 of 65), the third. Among the 56% (n = 40) receiving three injections, median drinks per day decreased from 4.1 (95% confidence interval = 2.9-6) at baseline to 0.5 (0-1.7) during Month 3. Extended-release naltrexone delivered in a primary care MM model appears a feasible and acceptable treatment for alcohol dependence.

Original languageEnglish (US)
Pages (from-to)14-21
Number of pages8
JournalJournal of Substance Abuse Treatment
Issue number1
StatePublished - Jul 2010


  • Alcohol medical management
  • Alcohol pharmacotherapy
  • Alcohol treatment
  • Extended-release naltrexone
  • Primary care

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Extended-release naltrexone for treatment of alcohol dependence in primary care'. Together they form a unique fingerprint.

Cite this